MaxCyte MXCT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.29M-2.2% | $33.03M-4.0% | $34.42M-3.7% | $35.75M-5.1% | $37.68M-2.5% | ||
| $6.29M+1.2% | $6.22M-9.7% | $6.89M-4.6% | $7.23M+0.4% | $7.19M+1.3% | ||
| $25.99M-3.0% | $26.8M-2.6% | $27.53M-3.5% | $28.53M-6.4% | $30.48M-3.3% | ||
| 80.5%-0.7pp | 81.2%+1.2pp | 80%+0.2pp | 79.8%-1.1pp | 80.9%-0.7pp | ||
| $18.78M-9.8% | $20.82M-5.8% | $22.1M0.0% | $22.1M+3.0% | $21.45M-3.5% | ||
| $16.65M-12.0% | $18.92M-13.6% | $21.89M-9.4% | $24.16M-3.3% | $25M-6.3% | ||
| $25.56M-9.1% | $28.12M-5.8% | $29.84M-5.4% | $31.56M+1.4% | $31.12M+4.8% | ||
| $4.18M-1.1% | $4.23M+0.5% | $4.21M+0.5% | $4.18M+1.1% | $4.14M-0.2% | ||
| —— | $3.55M— | —— | —— | —— | ||
| $71.78M-8.8% | $78.7M-3.0% | $81.1M-1.1% | $82.01M+0.4% | $81.7M-1.2% | ||
| $71.78M-8.8% | $78.7M-3.0% | $81.1M-1.1% | $82.01M+0.4% | $81.7M-1.2% | ||
| -$45.79M+11.8% | -$51.9M+3.1% | -$53.57M-0.2% | -$53.48M-4.4% | -$51.22M0.0% | ||
| -141.8%+15.3pp | -157.1%-1.5pp | -155.6%-6.1pp | -149.6%-13.6pp | -135.9%-3.4pp | ||
| $6.67M-8.2% | $7.27M-8.5% | $7.94M-8.8% | $8.7M-7.7% | $9.43M-7.0% | ||
| $6.67M-8.2% | $7.27M-8.5% | $7.94M-8.8% | $8.7M-7.7% | $9.43M-7.0% | ||
| -$39.12M+12.3% | -$44.63M+2.2% | -$45.63M-1.9% | -$44.77M-7.1% | -$41.79M-1.8% | ||
| —— | —— | —— | —— | —— | ||
| -$39.12M+12.3% | -$44.63M+2.2% | -$45.63M-1.9% | -$44.77M-7.1% | -$41.79M-1.8% | ||
| -121.2%+14.0pp | -135.1%-2.6pp | -132.6%-7.4pp | -125.2%-14.3pp | -110.9%-4.6pp | ||
| -$0.37+14.0% | -$0.43+2.3% | -$0.44-2.3% | -$0.43-7.5% | -$0.40-2.6% | ||
| -$0.37+14.0% | -$0.43+2.3% | -$0.44-2.3% | -$0.43-7.5% | -$0.40-2.6% | ||
| 426.3M+0.2% | 425.4M+0.4% | 423.8M+0.4% | 422.3M+0.4% | 420.5M+0.4% | ||
| 426.3M+0.2% | 425.4M+0.4% | 423.8M+0.4% | 422.3M+0.4% | 420.5M+0.4% | ||
| —— | $3.55M— | —— | —— | —— | ||
| $6.67M-8.2% | $7.27M-8.5% | $7.94M-8.8% | $8.7M-7.7% | $9.43M-7.0% | ||
| -$45.79M+11.8% | -$51.9M+3.1% | -$53.57M-0.2% | -$53.48M-4.4% | -$51.22M0.0% | ||
| -$41.5M+12.7% | -$47.56M+3.4% | -$49.25M-0.2% | -$49.16M-4.8% | -$46.92M-0.1% | ||
| -$41.5M+12.7% | -$47.56M+3.4% | -$49.25M-0.2% | -$49.16M-4.8% | -$46.92M-0.1% | ||
| -128.5%+15.5pp | -144%-0.9pp | -143.1%-5.6pp | -137.5%-13.0pp | -124.5%-3.2pp | ||
| -$45.79M+11.8% | -$51.9M+3.1% | -$53.57M-0.2% | -$53.48M-4.4% | -$51.22M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is MaxCyte's revenue?
- MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
- Is MaxCyte profitable?
- MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
- What are MaxCyte's profit margins?
- Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
- What is MaxCyte's earnings per share?
- MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
- Where does MaxCyte's income statement data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
